Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Slides:

Advertisements

Similar presentations

1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.

Advertisements

Richardson PG et al. Proc ASH 2013;Abstract 535.

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Palumbo A et al. Proc ASH 2014;Abstract 175.

R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.

1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.

R4 Jae Joon Han.

Multiple Myeloma: Is it now a curable disease?

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.

MRD testing: which platforms, which patients?

Overall Goal. Clinical Conversations: Nursing Care for Patients With Multiple Myeloma.

Palumbo A et al. Proc ASH 2012;Abstract 200.

GEM2005MAS65 Trial: Bortezomib-Based Maintenance Increases CR Rate and PFS in Elderly Patients With Newly Diagnosed Multiple Myeloma Slideset on: Mateos.

Attal M et al. Proc ASH 2010;Abstract 310.

Korde N et al. Proc ASH 2012;Abstract 732.

IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.

Mateos MV et al. Proc ASH 2013;Abstract 403.

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

Exploring Early Combination Therapy in PAH

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Perspectives on Triple-Negative Breast Cancer

Improving Survival in Glioblastoma Multiforme

Challenging Cases in Multiple Myeloma Panel Discussion

Post-autologous Transplant Therapy for Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Attal M et al. Proc ASCO 2010;Abstract 8018.

Treating Transplant-Ineligible Patients With Multiple Myeloma

Understanding Statin Metabolism

Goals of Therapy in Relapsed CLL

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Managing IBD in Children

Anthracycline Dose Intensification in Acute Myeloid Leukemia

Tailoring Hemophilia Prophylaxis Therapy

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Are We Closer to Personalized Medicine in MS?

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Vesole DH et al. Proc ASH 2010;Abstract 308.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA

Multiple Myeloma Overview all transplants, autologous and allogeneic (period ) N=28.887

Diagnosing Focal Epilepsy: A Clinical Case

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Approaches in Newly Diagnosed Multiple Myeloma: When and What

Revisiting the Pharmacoeconomics of HF

Staying Abreast of Best Practices Across the Clinical Continuum

Managing Multiple Myeloma in the Elderly

Grövdal M et al. Blood 2008;112:Abstract 223.

Program Goals Overview Is NEDA a Reasonable Target?

Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.

Hepatitis C: After the Diagnosis

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Updates on the Prevention and Management of CINV

The Role of Maintenance Therapy in Multiple Myeloma

Proteasome Inhibitors and Patients

First-Line FCR: Effect of del(17p) on PFS and OS

The Role of Measurable Residual Disease in AML

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

Minimal Residual Disease and Hematologic Malignancies

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Timing for HCT Consultation

Minimal Residual Disease in Multiple Myeloma

Maintenance therapies in Multiple Myeloma

Presentation transcript:

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma

Multiple Myeloma Choice of Induction Regimen

Multiple Myeloma Competing Induction Regimens

Choice of Induction Regimen Use the best drugs early to get maximum remission for as long as possible, both for the standard-risk as well as the high-risk patients.

Multiple Myeloma Early vs Delayed HDT/ASCT

Timing of HDT/ASCT Patients with no high-risk disease, who are responsive and tolerate therapy, may do extremely well with delayed HDT/ASCT.

Multiple Myeloma Maintenance Therapy

Consider No Maintenance For patients with standard-risk disease, stringent CR, normal FLC ratio, who are immunofixation negative in urine and serum, and have completely negative BM.

Consider Triplet Maintenance For patients with a truly high-risk disease (eg, stage III myeloma with high-risk cytogenetics).

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)